Several patent law issues will likely get attention from the U.S. Congress in 2020. These issues include efforts to reduce drug prices by limiting pharmaceutical patents and overhauling the patent eligibility law according to IP litigation partner Matt Rizzolo (Washington, D.C.) in comments published in Law360 on Jan. 1.
U.S. Supreme Court decisions like Mayo and Alice restricted the type of inventions that are eligible for patents, and critics of those rulings have complained that they have resulted in too many patents being found invalid and vague, with ambiguous standards on what can be patented.
The U.S. Senate Judiciary Committee's intellectual property subcommittee, met for months with industry groups to draft legislation to overhaul the patent eligibility law. Crafting language that would clarify patent eligibility standards, and doing so in a way that could be embraced by both the pharmaceutical and technology industries, appears to be difficult.
In this U.S. election year, Matt expects new bills aimed at curbing drug prices, with many of them included components that would alter patent law, including by restricting the number of patents that could cover any one drug.
Stay Up To Date with Ropes & Gray
Ropes & Gray attorneys provide timely analysis on legal developments, court decisions and changes in legislation and regulations.
Stay in the loop with all things Ropes & Gray, and find out more about our people, culture, initiatives and everything that’s happening.
We regularly notify our clients and contacts of significant legal developments, news, webinars and teleconferences that affect their industries.